1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > United States Off–Label Drugs Market & Forecast

United States Off–Label Drugs Market & Forecast

  • April 2015
  • -
  • Renub Research
  • -
  • 67 pages

Off–label prescribing of medicines is prevalent worldwide because it gives freedom to physicians to apply new therapeutic options based on the latest evidence. Although physicians may lawfully prescribe approved Drugs for any use consistent with available scientific data and proper medical practice, but unfortunately, this is done without adequate scientific data. Often, when the best available therapeutic option fails, patients demand new approach or new treatment which ultimately leads to off–label uses.

Off–label use is very common in United States. United States Off–label Drugs demand has grown at a fast pace in the past decade and likely to grow in the forecasting period. It is likely that United States off–label market will cross the figure of 60 Billion by the year 2020. Central Nervous System (CNS) and Cancer off–label Drugs controls the largest market share of the total US off–label Drugs market. Anti–Infectives Off–Label Drugs Market and Anti–Ashmatics Off–Label Drugs together are expected to control close to 35% market share by 2020.

Renub Research study titled “United States Off–Label Drugs Market & Forecast” report provides a comprehensive analysis of the emerging Off–Label Drugs market. The report also entails commonly prescribed Off–Label Drugs, Perspective of Physicians, Patients, Pharmaceutical Companies and Regulatory Authorities, Off–label Promotion Settlements under the False Claims Act. The report also studies Drivers and Challenges of United States Off–Label Drugs market. This 67 page report with 16 Figures and 1 Table studies 6 Off–Label Drugs Segment.

The 6 Off–Label Drugs Segment Covered in the Report are as Follows:

1. Cancer Off–Label Drugs
2. Central Nervous System (CNS) Off–Label Drugs
3. Anti–Ashmatics Off–Label Drugs
4. Anti–Allergies Off–Label Drugs
5. Anti–Hypertensives Off–Label Drugs
6. Anti–Infectives Off–Label Drugs

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephonic interviews with industry experts.

Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table Of Contents

United States Off-Label Drugs Market and Forecast
Table of Contents

1. Executive Summary

2. United States Off-Label Drugs Market and Forecast

3. United States Off-Label Drugs Market Share and Forecast

4. United States Off-Label Drugs Market - Segment wise

4.1 United States - Cancer Off-Label Drugs Market and Forecast
4.2 United States - Central Nervous System (CNS) Off-Label Drugs Market and Forecast
4.3 United States - Anti-Ashmatics Off-Label Drugs Market and Forecast
4.4 United States - Anti-Allergies Off-Label Drugs Market and Forecast
4.5 United States - Anti-Hypertensives Off-Label Drugs Market and Forecast
4.6 United States - Anti-Infectives Off-Label Drugs Market and Forecast

5. Drugs Commonly Prescribed Off-Label

6. Off-Label Use of Medicine and Different Perspectives

6.1 Physicians Perspective
6.1.1 Physicians' Liability for Off-Label Prescriptions
6.2 Patients Perspective
6.3 Perspective of the Pharmaceutical Companies
6.4 Perspective of Regulatory Agencies

7. Off-Label Promotion Settlements Under The False Claims Act

7.1 Year 2004
7.2 Year 2005
7.3 Year 2006
7.4 Year 2007
7.5 Year 2008
7.6 Year 2009
7.7 Year 2010
7.8 Year 2011
7.9 Year 2012
7.10 Year 2013
7.11 Year 2014

8. United States Off-Label Drugs Market - Growth Drivers

8.1 Clinical Practices and Application in the Off-Label Drugs
8.2 Vulnerable Patient Populations: Information and Access
8.3 Off-Label Promotion Reform

9. United States Off-Label Drugs Market - Challenges

9.1 Lack of Regulation and Information of the United States Off-Label Drugs Market
9.2 Reimbursement
9.3 Safety and Efficacy of Unapproved and Under Evaluated Use
9.4 Point of View on Bioethical Off-Label Drugs Use
9.5 Inaccuracy of Off-Label Clinical Publications


List of Figures

Figure 2-1: United States - Off-Label Drugs Market (Billion US$), 2011 - 2014
Figure 2-2: United States - Forecast for Off-Label Drugs Market (Billion US$), 2015 - 2020

Figure 3-1: United States - Off-Label Drugs Market Share (Percent), 2011 - 2014
Figure 3-2: United States - Forecast for Off-Label Drugs Market Share (Percent), 2015 - 2020

Figure 4-1: United States - Cancer Off-Label Drugs Market (Billion US$), 2008 - 2014
Figure 4-2: United States - Forecast for Cancer Off-Label Drugs Market (Billion US$), 2015 - 2020
Figure 4-3: United States - Central Nervous System (CNS) Off-Label Drugs Market (Billion US$), 2009 - 2014
Figure 4-4: United States - Forecast for Central Nervous System (CNS) Off-Label Drugs Market (Billion US$), 2015 - 2020
Figure 4-5: United States - Anti-Ashmatics Off-Label Drugs Market (Billion US$), 2010 - 2014
Figure 4-6: United States - Forecast for Anti-Ashmatics Off-Label Drugs Market (Billion US$), 2015 - 2020
Figure 4-7: United States - Anti-Allergies Off-Label Drugs Market (Billion US$), 2011 - 2014
Figure 4-8: United States - Forecast for Anti-Allergies Off-Label Drugs Market (Billion US$), 2015 - 2020
Figure 4-9: United States - Anti-Hypertensives Off-Label Drugs Market (Billion US$), 2009 - 2014
Figure 4-10: United States - Forecast for Anti-Hypertensives Off-Label Drugs Market (Billion US$), 2015 - 2020
Figure 4-11: United States - Anti-Infectives Off-Label Drugs Market (Billion US$), 2008 - 2014
Figure 4-12: United States - Forecast for Anti-Infectives Off-Label Drugs Market (Billion US$), 2015 - 2020

List of Tables

Table 5-1: Commonly Prescribed Off-Label Drugs

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy
Pharmaceutical
Cancer

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.